Noticias de Empresas

Burdinola Safer Labs Logo 04 150La firma Burdinola ha actualizado su imagen corporativa acorde a su nuevo modelo de negocio, renovando la concreción de la misión de la organización en correspondencia a la actual estrategia.

 

El reposicionamiento se materializa en el nuevo claim de su logotipo, que pasa a ser “Burdinola Safer labs”.

Oslo, Norway, 6 April 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that clinical data from the phase I/II clinical trial evaluating TG01 in resected pancreatic cancer will be presented at the American Society of Clinical Oncology ('ASCO') Annual Meeting 2017 at McCormick Place in Chicago, Illinois, 2-6 June 2017.

 

Paris, France and Cambridge, Massachusetts, April 4, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the expansion and acceleration of its clinical development activities. These include:

•        Acceleration of the head and neck cancer program. Phase I/II data will be presented at ASCO in June

•        Expansion of Nanobiotix's Immuno-Oncology program into patients focused on the objective of turning cold tumors into hot tumors. Nanobiotix will present the first clinical data from this program mid year

The annual general meeting was held on April 5, 2017 at the Company's offices at Lilleakerveien 2C, 0283 Oslo.

 

Please find minutes of the meeting attached.

Leuven (BELGIUM) - April 5, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company developing and commercializing novel therapeutics which exploit the anti-inflammatory properties of allogeneic, or donor-derived, stem cells, today announces that its management will be presenting at the 24th annual BioCentury Future Leaders in the Biotech Industry, New York, USA, and the Alliance for Regenerative Medicine (ARM) 5th Annual Cell and Gene Therapy Investor Day, Boston, USA. Tigenix will also be attending the 10th Kempen & Co Life Sciences Conference, Amsterdam, The Netherlands.

MerckMillipore100 99• New SMCxPRO™ technology offers high speed, high sensitivity for single molecule detection

• Meets customer demand for biomarker and novel target discovery and  detection

Operon100X40El año pasado, la pediatra Vega Almazán, junto a varios colaboradores más de diversas instituciones sanitarias de Granada (España), publicaba en la revista americana Reseach Pediatric un estudio sobre la prevalencia de la enfermedad celíaca en niños de entre 2 y 4 años, para el cual se utilizaron los tests rápidos de detección de celiaquía en sangre (CD1WB y CD2WB) desarrollados por OPERON.

3P60Pamplona, 5 de Abril de 2017. 3P Biopharmaceuticals ha firmado un acuerdo de colaboración con la australiana Ondek® -compañía biotecnológica especializada en el desarrollo de productos inmunomoduladores fundada por el Premio Nobel en Medicina Barry Marshall - para la producción de una innovadora inmunoterapia basada en el organismo Helicobacter pylori.

 

Operon100X40Nos complace informarles de que ya se encuentra disponible la agenda para el curso de Lateral Flow "Practicalities of Developing and Manufacturing Quantitative Assays". Puede consultarla AQUÍ.

Mechelen, Belgium, 4 April 2017 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the establishment of its US subsidiary, Biocartis US Inc., and the appointment of Vishal Sikri as its US General Manager. Both are important next steps in the execution of Biocartis' US strategy following the announced commercialization agreement with Thermo Fisher Scientific[1] Inc. in November 2016.

abyntek80

 

Nos complace anunciaros que hemos conseguido la distribución de dos nuevas casas comerciales: CUSAg y VLVbio.